Plasma Derived Medicine Market, By Product (Immunoglobulin, Coagulation factors, Albumin, and Others), By Application (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Infla

Plasma Derived Medicine Market, By Product (Immunoglobulin, Coagulation factors, Albumin, and Others), By Application (Pelvic Inflammatory Disease (PID), Bleeding Disorders, Alpha-1 Antitrypsin Deficiency (AATD), Hereditary Angioedema (HAE), Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Multifocal Motor Neuropathy, Liver Diseases, Primary Immune Thrombocytopenia, Infections, and Other Orphan Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Plasma derived medicines are manufactured using human blood plasma as the raw material. These medicines are used for treating various rare diseases like immune deficiency disorders, bleeding disorders, neurological disorders and more. Growing prevalence of rare diseases across the globe and advancements in therapy options can boost demand for plasma derived therapies. Furthermore, rising investments by government and private sectors in developing innovative treatments based on plasma derivatives can drive the market growth. However, high costs associated with plasma derived medication and stringent regulatory frameworks can hamper the market growth. Increasing emphasis on evidence-based treatment and emerging markets in developing nations can offer opportunities for plasma derived medicine providers in the near future.

Market Dynamics:

Global plasma derived medicine market growth is driven by rising prevalence of rare immunological and bleeding disorders worldwide. Growing adoption of plasma therapies to treat conditions like immune thrombocytopenia, hypogammaglobulinemia and neurological disorders can drive the market growth. Increasing healthcare spending coupled with evolving regulatory guidelines supporting manufacture of plasma derivatives can also drive the market growth. Emergence of innovative fractionation techniques and development of specialized bioprocessing infrastructure by market players facilitates the production of plasma derived drugs. However, high costs involved in plasma collection and complex production processes can hamper the rapid commercialization of plasma derived therapy. Stringent regulations regarding safety and efficacy evaluation can pose challenges for market players. Growing demand in emerging Asian and Latin American countries due to limited availability of alternative treatments can offer novel opportunities for manufacturers in the near future.

Key features of the study:

• This report provides in-depth analysis of the global plasma derived medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global plasma derived medicine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Takeda Pharmaceutical Company Ltd., CSL Ltd., Grifols S.A., Octapharma AG, and Kedrion S.p.A
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market

Detailed Segmentation-

• Product Insights (Revenue, USD Bn, 2019 - 2031)
• Immunoglobulin
• Coagulation factors
• Albumin
• Others
• Application Insights (Revenue, USD Bn, 2019 - 2031)
• Pelvic Inflammatory Disease (PID)
• Bleeding Disorders
• Alpha-1 Antitrypsin Deficiency (AATD)
• Hereditary Angioedema (HAE)
• Chronic Inflammatory Demyelinating Polyneuropathy
• Guillain-Barre Syndrome
• Multifocal Motor Neuropathy
• Liver Diseases
• Primary Immune Thrombocytopenia
• Infections
• Other Orphan Diseases
• Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Grifols, S.A.
• Octapharma AG
• Kedrion Biopharma
• LFB S.A.
• ADMA Biologics, Inc.
• Bio Products Laboratory Ltd.
• China Biologic Products Holdings, Inc.
• Shanghai RAAS Blood Products Co., Ltd.
• HemaCare Corporation
• Sanquin Blood Supply Foundation
• Biotest AG
• Emergent BioSolutions Inc.
• Medac GmbH
• Scripps Laboratories
• BPL (Bio Products Laboratory)
• Fresenius Kabi AG
• Kamada Pharmaceuticals